Yes on Issue 2: EpiPen Maker Mylan Caught Overcharging Medicaid $1.2 Billion; Agrees to $465M Settlement with Feds

Ethically-challenged drug company behind the EpiPen—which saw a 500%
price increase over the past decade—agrees to a landmark $465 million
settlement with the U.S. D.O.J.

Mylan overcharged Medicaid by $1.2 billion by misclassifying its
EpiPen as a generic instead of a brand-name product. The Justice
Department said Mylan’s move allowed it to pay smaller rebates to states
under Medicaid, the government insurance program for the poor.

COLUMBUS, Ohio–(BUSINESS WIRE)–Drug price advocates and people outraged over the price of Mylan, Inc.’s
lifesaving EpiPen and other lifesaving drugs, including supporters of
Ohio’s Yes on Issue 2 drug pricing ballot measure, applauded news of a
$465 million settlement or fine agreed to by Mylan with the United
States Department of Justice following the revelation that Mylan
overcharged state Medicaid programs by more than $1.2 billion.

According to news reports, including a news
article
in The Washington Times, the Justice Department said Mylan
overcharged Medicaid by $1.2 billion, “ … by misclassifying its
EpiPen as a generic instead of a brand-name product … The Justice
Department said Mylan’s move allowed it to pay smaller rebates to states
under Medicaid, the government insurance program for the poor.”

“It seems it was not enough for Mylan to raise the price of its
lifesaving EpiPen over 500% over the last decade—to $600 for a two-pack,
up from $57 per shot when it first took over sales of EpiPens in 2007,”
said Dennis Willard, spokesperson for the Yes on Issue 2
campaign. “For Medicaid rebate and reimbursement purposes, Mylan also
deliberately misclassified their products as generics in order that they
would have to pay much smaller rebates. The $1.2 billion Mylan gouged
from Medicaid could have paid for 200,000 EpiPen two-packs for those
suffering from life-threatening allergies, asthma and other conditions.
Mylan joins the upper ranks of greedy drug companies putting profits
before people, and offers yet another clear cut and compelling reason to
vote ‘Yes on Issue 2’ this November.”

“The greedy drug companies trying to defeat the Yes on Issue 2 campaign
to lower drug prices will say anything and do anything to protect their
excessive profits. Mylan’s actions speak volumes about the gimmicks that
greedy drug companies use to pretend they are lowering drug prices, when
in fact they are squeezing every dollar they can from the sick, the
suffering and unfortunately the dying patients they should be serving.
Vote yes on Issue 2 and send greedy drug companies like Mylan a powerful
message: Stop hurting Ohioans,” Willard added.

Background on Ohio Ballot Issue 2

The Yes on Issue 2 campaign is a broad-based, bi-partisan coalition.
More than 200,000 Ohio voters signed petitions to put an amendment on
the ballot in November that will lower drug prices for over 4 million
Ohioans, including 164,000 children, save taxpayers $400 million
annually, reduce healthcare costs for everyone and teach greedy drug
companies and their CEOs a lesson.

You can learn more by visiting yesonissue2.com or
following us on Facebook and Twitter.

Paid for by Ohio Taxpayers for Lower Drug Prices

Contacts

for Ohio Taxpayers for Lower Drug Prices
Dennis Willard,
614.209.8945
dennis@precisionnewmedia.com